This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Pfizer (PFE) stock slips after the company's lower than expected Q1 2025 revenue and the firm seeks acquisitions to boost its ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (PF-06882961) met key pharmacokinetic objectives. The study confirmed a formulation and dose that could deliver a ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral ...

Pfizer (NYSE:PFE) is overhauling its cardiometabolic pipeline and weighing acquisitions after an oral weight-loss candidate ...

Pfizer said dose-optimization studies of once-daily danuglipron showed that overall frequency of liver enzyme elevations across 1,400 study participants was in line with approved drugs in the class.

The company tested once-daily danuglipron formulations in a pair of phase 1 dose-optimization studies. Pfizer said the studies met key pharmacokinetic objectives and confirmed a formulation and ...

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the ...

Viking Therapeutics (VKTX) stock rises as Pfizer (PFE) plans to bolster its pipeline with cardiometabolic and other obesity drugs, through acquisitions. Read more here.